Haematopoietic stem cells (blood stem cells) are responsible for the regeneration of blood cells with their various tasks, e.g. oxygen transport, wound closure and immune defence.
Haematopoietic stem cell preparations are obtained from blood in circulation, from bone marrow or from cord blood and then placed in an anticoagulant solution. They are used fresh or are deep-frozen at temperatures below -140°C; for stem cell transplantation, stem cell preparations from the patient (autologous) or obtained from a donor (allogeneic) can be used.
Search results 351 to 355 from a total of 355
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
|
Cord Blood VITA 34 - 5 |
Vita 34 AG |
PEI.H.00601.01.1 | 14.10.2006 | |
|
Autologes Nabelschnurblut VITA 34-2/3 |
VITA 34 AG |
PEI.G.03988.02.1 | 19.01.2012 | |
|
Cord Blood VITA 34 mini |
Vita 34 AG |
PEI.H.00601.03.1 | 20.12.2007 | |
|
Cord Blood VITA 34 - 2,5 |
Vita 34 AG |
PEI.H.00601.02.1 | 14.10.2006 | |
|
Stammzellzubereitung und Kryokonservierung aus autologem peripherem Blut WPK |
Westpfalz-Klinikum GmbH |
PEI.G.03688.01.1 | 14.12.2011 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 518 in BAnz AT 26.06.2024 B7.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 26.06.2024
